Section Arrow
SAGE.NASDAQ
- Sage Therapeutics
Quotes are at least 15-min delayed:2024/10/31 19:27 EDT
Last
 6.085
-0.355 (-5.51%)
Day High 
6.59 
Prev. Close
6.44 
1-M High
8.7 
Volume 
1.38M 
Bid
6.06
Ask
6.48
Day Low
5.915 
Open
6.39 
1-M Low
5.8401 
Market Cap 
393.16M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 7.72 
20-SMA 7.22 
50-SMA 7.48 
52-W High 28.26 
52-W Low 5.8401 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.41/-5.55
Enterprise Value
393.16M
Balance Sheet
Book Value Per Share
10.29
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
86.46M
Operating Revenue Per Share
18.24
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ELABElevai Labs0.059-0.0339-36.49%-- 
AVTEAerovate Therapeutics2.46+0.27+12.33%-- 
ENSCEnsysce Biosciences0.5754-0.0629-9.85%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.1445-0.0099-6.41%-- 
GLYCGlycoMimetics0.4069-0.0496-10.87%-- 
Quotes are at least 15-min delayed:2024/10/31 19:27 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; alsotargeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment ofpostpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.